Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunotherapy With MK-3475 in Surgically Resectable Endometrial Carcinoma

Trial Profile

Immunotherapy With MK-3475 in Surgically Resectable Endometrial Carcinoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Endometrial cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Nov 2020 Status changed from active, no longer recruiting to completed.
    • 28 Aug 2019 Planned End Date changed from 28 Feb 2021 to 3 Oct 2020.
    • 04 Jun 2019 Interim results of biomarker analysis from patients with pathological response presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top